These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32703752)

  • 1. How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis).
    Chaulagain CP; Herlitz LC; Fu J; Bilani N; Lucitt C; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e826-e831. PubMed ID: 32703752
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolving Role of Autologous Stem Cell Transplantation for Light Chain Amyloidosis in the Modern Era.
    Baljevic M
    Oncology (Williston Park); 2021 Aug; 35(8):474-475. PubMed ID: 34398595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Autologous Stem Cell Transplantation in Amyloidosis.
    Vaxman I; Dispenzieri A
    Oncology (Williston Park); 2021 Aug; 35(8):471-478. PubMed ID: 34398591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Saliba RM; Hamdi A; Honhar M; Varma A; Cornelison AM; Rondon G; Parmar S; Shah ND; Bashir Q; Hosing C; Popat U; Weber DM; Thomas S; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2197-2203. PubMed ID: 30016656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective.
    Badar T; Hari P; Chhabra S; Dhakal B; Drobyski WR; Fenske TS; Hamadani M; Pasquini M; Saber W; Shah NN; Shaw BE; D'Souza A
    Bone Marrow Transplant; 2018 Sep; 53(9):1210-1213. PubMed ID: 29679076
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Saliba RM; Hamdi A; El Fakih R; Varma A; Dinh YT; Rondon G; Cornelison AM; Shah ND; Bashir Q; Shah JJ; Hosing C; Popat U; Orlowski RZ; Champlin RE; Parmar S; Qazilbash MH
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1413-7. PubMed ID: 25842049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.
    Nasr SH; Said SM; Valeri AM; Sethi S; Fidler ME; Cornell LD; Gertz MA; Dispenzieri A; Buadi FK; Vrana JA; Theis JD; Dogan A; Leung N
    Kidney Int; 2013 Mar; 83(3):463-70. PubMed ID: 23302715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA
    Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis.
    Furtado VF; Brauneis D; Weinberg J; Elhassan N; Sloan JM; Sanchorawala V
    Bone Marrow Transplant; 2022 Feb; 57(2):306-308. PubMed ID: 34845368
    [No Abstract]   [Full Text] [Related]  

  • 12. Non-light-chain immunoglobulin amyloidosis: time to expand or refine the spectrum to include light+heavy chain amyloidosis?
    Picken MM
    Kidney Int; 2013 Mar; 83(3):353-6. PubMed ID: 23446254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy.
    Mellgard GS; Bhutani D; Mapara MY; Maurer MS; Radhakrishnan J; Lentzsch S; Chakraborty R
    Bone Marrow Transplant; 2024 Aug; 59(8):1181-1183. PubMed ID: 38724598
    [No Abstract]   [Full Text] [Related]  

  • 14. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
    Cordes S; Gertz MA; Buadi FK; Lin Y; Lacy MQ; Kapoor P; Kumar SK; McCurdy A; Dispenzieri A; Dingli D; Hayman SR; Hogan WJ; Pruthi RK
    Blood Coagul Fibrinolysis; 2016 Jan; 27(1):101-8. PubMed ID: 26218969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
    Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of bortezomib in the induction, conditioning and consolidation with autologous hematopoietic stem cell transplantation in patients with immunoglobulin light chain amyloidosis.
    Huang X; Fu C; Chen L; Chen W; Ren G; Guo J; Zhao L; Zeng C; Zhang H; Gong D; Ren Q; Liu Z
    Am J Hematol; 2019 Apr; 94(4):E101-E104. PubMed ID: 30652338
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
    Abdallah AA; Alapat D; Kaur V; Atrash S
    J Oncol Pharm Pract; 2020 Jul; 26(5):1128-1133. PubMed ID: 31795821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
    Chen W; Ren G; Zuo K; Huang X
    Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
    Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.